Cardiac allograft vasculopathy (CAV) remains the Achilles' heel of long-term survival after
heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant …

The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus are
increasingly used in cardiothoracic transplantation. Several recent clinical trials have …

Background Pregnancies may result in antibodies against HLA, a risk factor for antibody-
mediated rejection (AMR) and subsequent cardiac allograft vasculopathy (CAV) after heart …

Chronic allograft vasculopathy (CAV) limits the lifespan of pediatric heart transplant
recipients. We investigated blood markers of inflammation, endothelial dysfunction, and …

Normal aging is accompanied by cognitive impairment with subtle cellular and molecular
changes in the brain, whereas, pathological brain aging manifests as severe behavioral …

Objectives: Although there have been tremendous advancements in the care of severe
pediatric cardiovascular disease, heart transplantation remains the standard therapy for end …

Background Elevated immune monitoring (IM), as measured by adenosine triphosphate
(ATP) release from activated lymphocytes, has been suggested to represent an under …

Successful organ transplantation requires immunosuppression, however current
immunosuppressants have significant side effects, particularly nephrotoxicity. Mammalian …

Refractory angina pectoris (RAP) is a clinical problem, frequently encountered in the elderly,
associated with high health-care costs. Until recently, the goal of RAP treatment aimed at …

The use of inhibitors of the mammalian target of rapamycin (mTORi) is gaining popularity as
a long-term immunosuppressant, in part because of their anti-proliferative effects, which may …